Relationship Between Multiple Sclerosis and Osteoporosis in Postmenopausal Women; A Case Report and Brief Review of the Literature

Article Sidebar

PDF
Published: Nov 15, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i11-25
Keywords:
Multiple sclerosis, osteoporosis, bone mineral density, vitamin D, bone metabolism, postmenopausal, RANKL, bone density and steroids

Main Article Content

Susana Gámez Flores
Specialist in Gynecology and Obstetrics associated with the College of Gynecology and Obstetrics of Jalisco & the Mexican Association of Mineral and Bone Metabolism.
Karina Lamadrid Gámez
Resident of Internal Medicine at the San Javier Hospital in Guadalajara.
Javier Contreras Cárdenas
Faculty of Psycology of National Autonomous of Mexico, Intern Physician of the Social Service at the San Juan de Dios Hospital in Zapopan
Ivan Eduardo Meraz Nieto
Intern Physician of the social service at the Hospital Lomas Providencia in Guadalajara.

Abstract

Multiple sclerosis and osteoporosis are diseases that its comorbidity usually affects on postmenopausal women, certain evidence shows share pathogenic ways, and inclusively it’s been proved that peri-pathogenic situations with certain treatments can predisposed patients with this pathology neurodegenerative to imbalance the bone density system. In this article we stablished what the multiple sclerosis and osteoporosis are, we investigate if there’s a relationship between them and tried to explain more than a “casual statistic of comorbids” , also we use as an example this situation with an archetypal case report that represent exactly this type of patients.

Article Details

How to Cite
Flores, S. G., Gámez, K. L. ., Cárdenas, J. C. ., & Meraz Nieto, I. E. (2022). Relationship Between Multiple Sclerosis and Osteoporosis in Postmenopausal Women; A Case Report and Brief Review of the Literature. International Journal of Medical Science and Clinical Research Studies, 2(11), 1287–1292. https://doi.org/10.47191/ijmscrs/v2-i11-25
Issue
Vol. 2 No. 11 (2022): Volume 02 Issue 11 November 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Clark, P., Carlos, F., & Vázquez Martínez, J. L. (2010). Epidemiology, costs and burden of osteoporosis in Mexico. Archives of Osteoporosis, 5(1-2), 9–17.

https://doi.org/ 10.1007/s11657-010-0042-8

II. Cuevas-García, C. (2017). Esclerosis múltiple: Aspectos inmunológicos actuales. Revista Alergia México, 64(1),

–86. https://doi.org/10.29262/ram.v64i1.253

III. Filippi, M. (2018). Multiple sclerosis. Nature Reviews Disease Primers, 4(1). https:// doi.org/10.1038/s41572-018-0046-z

IV. Huang, Z., Qi, Y., Du, S., Chen, G., & Yan, W. (2014). BMI levels with Ms Bone mineral density levels in adults with multiple sclerosis: A meta-analysis. International Journal of Neuroscience, 125(12), 904–912. https://doi.org/10.3109/00207454.2014.988332

V. Dobson, R., & Giovannoni, G. (2018). Multiple sclerosis – A Review. European Journal of Neurology, 26(1), 27–40. https://doi.org/10.1111/ene.13819

VI. Weiner, H. L. (2004). Multiple sclerosis is an inflammatory T-cell–mediated autoimmune disease. Archives of Neurology, 61(10), 1613.

https://doi.org/10.1001/ archneur.61.10.1613

VII. Clarke, B. L., & Khosla, S. (2010). Physiology of bone loss. Radiologic Clinics of North America, 48(3), 483–495. https://doi.org/10.1016/j.rcl.2010.02.014

VIII. Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis. BMJ. 2015;350:h1765. Published 2015 Apr 14. doi:10.1136/bmj.h1765

IX. M u r r a y T J. D i a g n o s i s a n d t r e a t m e n t o f m u l t i p l e s c l e r o s i s. B M J. 2006;332(7540):525-527.

doi:10.1136/bmj.332.7540.525

X. Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003). Osteoclast differentiation and activation. Nature, 423(6937), 337–342.

https://doi.org/10.1038/nature01658

XI. Diagnosis and differential diagnosis. (2003). Multiple Sclerosis in Clinical Practice, 55– 102. https://doi.org/10.1201/b14727-5

XII. Khosla, S. (2001). Minireview: The OPG/rankl/rank system. Endocrinology, 142(12), 5050–5055.

https://doi.org/10.1210/endo.142.12.8536

XIII. Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003). Role of rank ligand in mediating increased bone resorption in early postmenopausal women. Journal of Clinical Investigation, 111(8), 1221–1230. https://

doi.org/10.1172/jci200317215

XIV. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89(2), 309–319. https://doi.org/10.1016/s0092-8674(00)80209-3

XV. Eastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016). Postmenopausal osteoporosis. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.69

XVI. Svedbom, A., Hernlund, E., Ivergård, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E. V., Jönsson, B., & Kanis, J. A. (2013). Osteoporosis in the European Union: A compendium of country-specific reports. Archives of Osteoporosis, 8(1-2).

https://doi.org/10.1007/s11657-013-0137-0

XVII. Muñoz-Torres, M., Higuera López-Frías, M. de, & Fernández García, D. (2004). Avances en el conocimiento de la biología del osteoclasto: El Sistema Osteoprotegerina-Ligando del rank. Medicina Clínica, 122 (2 ) , 75 – 77 . https:// doi. org/ 10. 1016 / s0025-7753(04)74146-9.

XVIII. Lips, P. (2006). Vitamin D physiology. Progress in Biophysics and Molecular Biology, 92(1), 4–8. https://doi.org/10.1016/j.pbiomolbio.2006.02.016

XIX. Sintzel, M. B., Rametta, M., & Reder, A. T. (2017). Vitamin D and multiple sclerosis: A comprehensive review. Neurology and Therapy, 7(1), 59–85. https://doi.org/10.1007/ s40120-017-0086-4

XX. Ascherio, A., Munger, K. L., & Simon, K. C. (2010). Vitamin D and multiple sclerosis. The Lancet Neurology, 9(6), 599–612.

https://doi.org/10.1016/s1474-4422(10)70086-7

XXI. Oliveros A., William Darío, & Mikán V., José Fernando (2007). Osteoclastogénesis y enfermedades óseas. Revista Med, 15(2),261-270. [fecha de Consulta 14 de Junio de 2022]. ISSN: 0121-5256. Disponible en: https://www.redalyc.org/articulo.oa? id=91015213

XXII. Gutiérrez-Polo, R. (2003). Osteoporosis inducida por glucocorticoides. Anales del Sistema Sanitario de Navarra, 26(Supl. 3), 63-80. Recuperado en 14 de junio de 2022, de h t t p: / / s c i e l o. i s c i i i. e s / s c i e l o. p h p? script=sci_arttext&pid=S1137-

&lng=es&tlng=es.

XXIII. Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006). Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 296(23), 2832. https:// doi.org/10.1001/jama.296.23.2832

XXIV. Valero Zanuy, M. Á., & Hawkins Carranza, F. (2007). Metabolismo, Fuentes Endógenas y exógenas de vitamina D. Revista Española De Enfermedades Metabólicas Óseas, 16(4), 63–70.

https://doi.org/10.1016/s1132-8460(07)73506-7

XXV. Sintzel, M. B., Rametta, M., & Reder, A. T. (2017). Vitamin D and multiple sclerosis: A comprehensive review. Neurology and Therapy, 7(1), 59–85. https://doi.org/10.1007/ s40120-017-0086-4